SML3961

Paricalcitol

≥98% (HPLC)

• Sinónimos: (1R,3R)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5S,E)-6-hydroxy-5,6-dimethylhept-3-en-2-yl)-7a-methyldihydro-1H-inden-4(2H,5H,6H,7H,7aH)-ylidene)ethylidene)cyclohexane-1,3-diol, (1alpha.3beta,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol, (7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol, 19-Nor-1alpha,25-dihydroxyvitamin D2
• Fórmula empírica (notación de Hill): C₂₇H₄₄O₃
• Número de CAS: 131918-61-1
• Peso molecular: 416.64
• UNSPSC Code: 12352200
• NACRES: NA.77

Propiedades

• Quality Level: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: -10 to -25°C
• SMILES string: OC1CC(CC(=CC=C2C3C(C(CC3)C(C)C=CC(C(O)(C)C)C)(CCC2)C)C1)O
• InChI key: BPKAHTKRCLCHEA-UHFFFAOYSA-N

Descripción

Biochem/physiol Actions

Agonist for the calcitriol (Vitamin D receptor); Vitamin D analog; Antihyperparathyroid.

Paricalcitol is Vitamin D analog that acts as an agonist for the calcitriol receptor (Vitamin D receptor, VDR). It suppresses parathyroid hormone (PTH) gene transcription and PTH secretion and has been used clinically because of its antihyperparathyroid activity without inducing hypercalcemia or hyperphosphatemia. There is growing evidence that vitamin D either directly or indirectly affects cardiac structure and function. Paricalcitol showed improvement of cardiac function after myocardial infarction in mice with decreases in biomarkers, apoptosis, inflammation, and fibrosis.

Información de seguridad

• pictograms: GHS06,GHS08
• signalword: Danger
• hcodes: H301 + H311,H330,H372
• pcodes: P260 - P264 - P280 - P302 + P352 + P312 - P304 + P340 + P310 - P314
• Hazard Classifications: Acute Tox. 2 Inhalation - Acute Tox. 3 Dermal - Acute Tox. 3 Oral - STOT RE 1 Oral
• Storage Class: 6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable